Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB12 (Pembrolizumab Biosimilar) vs Keytruda in Advanced Non-Squamous NSCLC (BENITO)
NCT06687369Phase 3Active, not recruiting
- Sponsor
- mAbxience
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of Pembrox in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (3 arms), sponsored by mAbxience. Primary endpoints: Pharmacokinetic Bioequivalence and Efficacy Equivalence. Started Dec 2024; status: active, not recruiting.
02
Drugs
Pembrox
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06687369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687369.